

**Freedom of Information Request**

**Ref: UHB 19-547**

27 September 2019

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

**Question 1a**

Does your trust treat advanced breast cancer ?

Yes.

**Question 1b**

If none, where are your patients referred?

N/A.

**Question 2**

In the past 3 months, how many advanced breast cancer patients [Stage IV] have the status of:

HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive].

HR+ and HER2- [Hormone receptor-positive and human epidermal growth factor 2-negative].

HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive].

HR- and HER2- [Hormone receptor-negative and human epidermal growth factor 2-negative]

- Triple negative disease.

The Trust does not hold this information. If it relates to newly diagnosed patients then the breast Multi-Disciplinary Team at North Bristol NHS Trust should be contacted to answer this question.

**Question 3**

In the past 3 months, how many breast cancer patients were treated with:

Abemaciclib (Verzenios) + aromatase inhibitor \* - 6

Abemaciclib (Verzenios) + Fulvestrant (Faslodex) - 15

Alpelisib (Piqray) + Fulvestrant (Faslodex) - 0

Atezolizumab (Tecentriq)\*\* - 0  
Bevacizumab (Avastin) - 0  
Eribulin (Halaven) - 3  
Everolimus (Afinitor) + Exemestane - 2  
Fulvestrant (Faslodex) as a single agent - 2  
Gemcitabine + paclitaxel - 0  
Lapatinib (Tyverb) - 0  
Neratinib (Nerlynx) - 2  
Olaparib (Lynparza) - 0  
Palbociclib (Ibrance) + aromatase inhibitor\* - 42  
Pertuzumab (Perjeta) + trastuzumab + docetaxel - 3  
Ribociclib (Kisqali) + aromatase inhibitor\* - 0  
Ribociclib (Kisqali) + Fulvestrant (Faslodex) - 0  
Talazoparib (Talzenna) - 0  
Trastuzumab + paclitaxel - 8  
Trastuzumab as a single agent - 108  
Trastuzumab emtansine (Kadcyla) - 9  
Other active systemic anti-cancer therapy \*\* - 175

\*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole

\*\*eg. docetaxel, vinorelbine or capecitabine as a single agent

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Trust Secretary  
University Hospitals Bristol NHS Foundation Trust  
Trust Headquarters  
Marlborough Street  
Bristol  
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

**FOI Team**  
**UH Bristol NHS Foundation Trust**